EPISODE · Apr 17, 2026 · 35 MIN
Episode 153 - Lan Huang - CEO of SEED Therapeutics
from The BioHub: The Top Voices in Biotech · host Max Brennan - Biotech HeadHunter
Today’s guest sits at the intersection of cutting-edge science and bold entrepreneurship. Dr. Lan Huang is the Co-Founder, CEO, and Chairman of SEED Therapeutics, where she’s leading the charge in developing next-generation medicines through targeted protein degradation—an approach that’s redefining what’s possible in drug discovery.But she didn’t stop at the lab bench. Lan is also a seasoned biotech entrepreneur, having founded multiple companies across the U.S. and China, including BeyondSpring, which she led to a successful public listing. Across more than 15 years in the industry, she’s built a reputation for translating complex science into real-world treatments.In this episode, we explore her journey from researcher to CEO, the promise of molecular glue therapies, and what it takes to build a biotech company at the frontier of innovation.
What this episode covers
Today’s guest sits at the intersection of cutting-edge science and bold entrepreneurship. Dr. Lan Huang is the Co-Founder, CEO, and Chairman of SEED Therapeutics, where she’s leading the charge in developing next-generation medicines through targeted protein degradation—an approach that’s redefining what’s possible in drug discovery.But she didn’t stop at the lab bench. Lan is also a seasoned biotech entrepreneur, having founded multiple companies across the U.S. and China, including BeyondSpring, which she led to a successful public listing. Across more than 15 years in the industry, she’s built a reputation for translating complex science into real-world treatments.In this episode, we explore her journey from researcher to CEO, the promise of molecular glue therapies, and what it takes to build a biotech company at the frontier of innovation.
NOW PLAYING
Episode 153 - Lan Huang - CEO of SEED Therapeutics
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m